Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 bridging study of ALXN2050 in healthy Japanese participants
NCT04952545Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) and myasthenia gravis (MG) (4 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoints: Number Of Participants With Treatment-emergent Adverse Events, Area Under The Concentration-time Curve From Time Zero To Infinity (AUCinf) For Single-dose ALXN2050 and 5 more. Started Jul 2021; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04952545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952545.